1. Home
  2. TALK vs OMER Comparison

TALK vs OMER Comparison

Compare TALK & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Talkspace Inc.

TALK

Talkspace Inc.

HOLD

Current Price

$5.20

Market Cap

788.5M

Sector

Health Care

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$10.94

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TALK
OMER
Founded
2012
1994
Country
United States
United States
Employees
521
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
788.5M
772.8M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
TALK
OMER
Price
$5.20
$10.94
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$6.42
$32.50
AVG Volume (30 Days)
1.3M
1.4M
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.15
EPS
N/A
0.62
Revenue
N/A
$29,868,000.00
Revenue This Year
$26.02
N/A
Revenue Next Year
$21.24
$233.22
P/E Ratio
$155.55
$17.95
Revenue Growth
N/A
N/A
52 Week Low
$2.22
$2.95
52 Week High
$5.20
$17.65

Technical Indicators

Market Signals
Indicator
TALK
OMER
Relative Strength Index (RSI) 55.78 33.80
Support Level $4.59 $10.82
Resistance Level $5.20 $12.06
Average True Range (ATR) 0.01 0.83
MACD -0.00 -0.32
Stochastic Oscillator 50.50 12.73

Price Performance

Historical Comparison
TALK
OMER

About TALK Talkspace Inc.

Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: